Sector News

With big debt on tap, analysts see Takeda-Shire deal as 'more likely than not'

April 6, 2018
Life sciences

After Takeda revealed last week that it was eyeing a Shire buy, industry watchers expressed skepticism that the company could pull it off. Now, though, some analysts like the Japanese drugmaker’s chances.

In a Thursday meeting, Takeda told analysts it was “willing to push its debt higher” in order to seal the deal, Bernstein’s Wimal Kapadia wrote to clients. And in light of that fact, he now sees a potential transaction as “more likely than not.”

“We think the deal is likely because there is willing buyer, willing sellers and room to meet both sides’ expectations,” he wrote.

Shire shares have been struggling hard; new hemophilia competition from Roche has prevented them from bouncing back after a less-than-stellar Baxalta buy that left the company “too levered to do anything itself” as far as M&A goes.

But while “Shire stand-alone struggles with negative earnings revisions and lack of catalysts in the near-term,” Takeda can afford to wait for the tide to turn. “The objective for Takeda is 2025 positioning,” Kapadia pointed out.

Of course, just because Shire shareholders are open to a sale doesn’t mean there’s overlap between the price they want and what Takeda’s willing to lay down, he noted. According to a Bernstein survey, investors are hoping for £42/$175 per share to kick off negotiations and £45/$190 to ink an agreement—as well as less than 50% in Takeda shares.

Other analysts had previously voiced doubts that Takeda could afford a Shire buy after its interest announcement sank shares but sent Shire’s soaring.

But the way Kapadia sees things, Takeda can probably get it done thanks to a willingness to go to 5x leverage and the opportunity to issue shares locally, which would reduce the shares issued to Shire investors.

“We believe the local market will be willing to absorb more Takeda stock given the positive local headlines and limited share movement down since the deal has been announced,” Kapadia wrote.

Meanwhile, the pharma intends to drum up some extra cash with a sale of its Brazil-based pharma unit, Multilab Indústria e Comércio de Produtos Farmacêuticos, Reuters reported. Takeda plans to offload the business to Novamed Fabricação de Produtos Farmacêuticos in June at an undisclosed price.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).